News | November 11, 2014

TIDI Products Acquires CFI, Maker of Cath Lab Radiation Protection Equipment

Acquisition enhances radiation protection offerings in the cath lab

November 11, 2014 — TIDI Products LLC has acquired CFI Medical Solutions (CFI) of Fenton, Mich., a diversified medical device manufacturer and engineering resource for hospitals, distributors and global original equipment manufacturers.

CFI has expertise in the design, engineering and manufacturing of radiation protection, infection prevention and patient positioning systems that help clinicians improve the effectiveness of their practices and healthcare systems. The company’s innovation process is collaborative, developing products by working side-by-side with clinicians and physicians.

“We’ve seen some of the value added innovations, such as C-Armor and Zero-Gravity that CFI has developed in partnership with its healthcare professional network” said Kevin McNamara, president and CEO of TIDI. “We look forward to adopting CFI’s culture of innovative thinking throughout our business to further enhance TIDI’s mission of supporting caregivers and preventing infections.”

C-Armor is an expandable and collapsible sterile pouch that adheres to the patient drape at or above the level of the sterile field line during surgical procedures. Zero-Gravity is a suspended radiation protection system that provides greater protection to clinicians during fluoroscopic procedures.

Headquartered in Neenah, Wis., TIDI plans to continue CFI’s engineering and manufacturing operations for its domestic and international customers. CFI employs approximately 300 people at its manufacturing locations in Fenton, Mich., and its Changshu Yushan Protection Products Co. Ltd. facility in Changshu, China.

For more information: www.tidiproducts.com, www.cfimedical.com

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init